HRP20161459T1 - Protutijela koja se specifično vežu na receptor epidermnog čimbenika rasta - Google Patents
Protutijela koja se specifično vežu na receptor epidermnog čimbenika rasta Download PDFInfo
- Publication number
- HRP20161459T1 HRP20161459T1 HRP20161459TT HRP20161459T HRP20161459T1 HR P20161459 T1 HRP20161459 T1 HR P20161459T1 HR P20161459T T HRP20161459T T HR P20161459TT HR P20161459 T HRP20161459 T HR P20161459T HR P20161459 T1 HRP20161459 T1 HR P20161459T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- cdr
- encodes
- acid sequence
- Prior art date
Links
- 102000001301 EGF receptor Human genes 0.000 title claims 7
- 108060006698 EGF receptor Proteins 0.000 title claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 13
- 239000002773 nucleotide Substances 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000013604 expression vector Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Protutijelo koje se specifično veže na receptor epidermnog čimbenika rasta (EGFR), naznačeno time što sadrži:
a) varijabilno područje teškog lanca koje sadrži područje za određivanje komplementarnosti (CDR) 1, CDR 2, te CDR 3 koja imaju aminokiselinske sljedove sa SEQ ID NO: 1, 2, odnosno 3;
b) varijabilno područje lakog lanca koje sadrži CDR 1, CDR 2, te CDR 3 koji imaju aminokiselinske sljedove sa SEQ ID NO: 4, 5, odnosno 6;
c) konstantno područje teškog lanca; i
d) konstantno područje lakog lanca.
2. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što sadrži:
a) varijabilno područje teškog lanca koje ima aminokiselinski slijed sa SEQ ID NO: 7;
b) varijabilno područje lakog lanca koje ima aminokiselinski slijed sa SEQ ID NO: 8;
c) konstantno područje teškog lanca; i
d) konstantno područje lakog lanca.
3. DNA, naznačena time što kodira varijabilno područje teškog lanca protutijela koje sadrži CDR 1, CDR 2, te CDR 3 koji imaju aminokiselinske sljedove sa SEQ ID NO: 1, 2, odnosno 3; te DNA koja kodira varijabilno područje lakog lanca protutijela koje sadrži CDR 1, CDR 2, te CDR 3 koji imaju aminokiselinske sljedove sa SEQ ID NO: 4, 5, odnosno 6; gdje se protutijelo specifično veže na receptor epidermnog čimbenika rasta (EGFR).
4. DNA u skladu s patentnim zahtjevom 3, naznačena time što sadrži polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 11, koji kodira aminokiselinski slijed sa SEQ ID NO: 1, polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 12, koji kodira aminokiselinski slijed sa SEQ ID NO: 2, te polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 13, koji kodira aminokiselinski slijed sa SEQ ID NO: 3; te što sadrži polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 15, koji kodira aminokiselinski slijed sa SEQ ID NO: 4; polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 16, koji kodira aminokiselinski slijed sa SEQ ID NO: 5; te polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 17, koji kodira aminokiselinski slijed sa SEQ ID NO: 6.
5. DNA u skladu s patentnim zahtjevom 3, naznačena time što kodira varijabilno područje teškog lanca protutijela koje ima aminokiselinski slijed sa SEQ ID NO: 7; te što kodira varijabilno područje lakog lanca protutijela koje ima aminokiselinski slijed sa SEQ ID NO: 8.
6. DNA u skladu s patentnim zahtjevom 5, naznačena time što sadrži polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 14, koji kodira aminokiselinski slijed sa SEQ ID NO: 7; te što sadrži polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 18, koji kodira aminokiselinski slijed sa SEQ ID NO: 8.
7. Ekpresijski vektor za ekprimiranje varijabilnog područja teškog lanca i varijabilnog područja lakog lanca protutijela koje se specifično veže na receptor epidermnog čimbenika rasta (EGFR), naznačen time što sadrži DNA u skladu s patentnim zahtjevom 3.
8. Ekpresijski vektor u skladu s patentnim zahtjevom 7, naznačen time što je ER2-Heavy-pRC13, čija je mapa prikazana na Sl. 5; te što je ER2-Light-pKC12, čija je mapa prikazana na Sl. 6.
9. Životinjska stanična linija, naznačena time što je transformirana ekpresijskim vektorom u skladu s patentnim zahtjevom 7.
10. Pripravak za liječenje rak, naznačen time što sadrži protutijelo u skladu s patentnim zahtjevom 1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090092401A KR101108642B1 (ko) | 2009-09-29 | 2009-09-29 | 표피 성장 인자 수용체에 특이적으로 결합하는 항체 |
| PCT/KR2009/006380 WO2011040668A1 (en) | 2009-09-29 | 2009-11-02 | Antibodies specifically binding to the epidermal growth factor receptor |
| EP09850100.0A EP2483309B1 (en) | 2009-09-29 | 2009-11-02 | Antibodies specifically binding to the epidermal growth factor receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161459T1 true HRP20161459T1 (hr) | 2016-12-16 |
Family
ID=43826456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161459TT HRP20161459T1 (hr) | 2009-09-29 | 2016-11-03 | Protutijela koja se specifično vežu na receptor epidermnog čimbenika rasta |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8748175B2 (hr) |
| EP (1) | EP2483309B1 (hr) |
| JP (1) | JP5729839B2 (hr) |
| KR (1) | KR101108642B1 (hr) |
| CN (1) | CN102574919B (hr) |
| BR (1) | BR112012007082B1 (hr) |
| CA (1) | CA2774427C (hr) |
| DK (1) | DK2483309T3 (hr) |
| ES (1) | ES2592883T3 (hr) |
| HR (1) | HRP20161459T1 (hr) |
| HU (1) | HUE030733T2 (hr) |
| LT (1) | LT2483309T (hr) |
| MX (1) | MX2012003662A (hr) |
| MY (1) | MY163502A (hr) |
| PL (1) | PL2483309T3 (hr) |
| PT (1) | PT2483309T (hr) |
| RU (1) | RU2518239C2 (hr) |
| SI (1) | SI2483309T1 (hr) |
| WO (1) | WO2011040668A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110317259A (zh) | 2012-03-27 | 2019-10-11 | 株式会社绿十字 | 表皮生长因子受体表面抗原的表位及其用途 |
| US9921222B2 (en) | 2012-07-31 | 2018-03-20 | Crown Bioscience, Inc. (Taicang) | Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-EGFR drug |
| CN102993305B (zh) * | 2012-11-16 | 2015-05-13 | 上海赛伦生物技术有限公司 | 人源抗人表皮生长因子受体抗体及其编码基因与应用 |
| CN104341505A (zh) * | 2013-07-29 | 2015-02-11 | 西藏海思科药业集团股份有限公司 | 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体 |
| KR102089591B1 (ko) * | 2013-07-29 | 2020-03-18 | 삼성전자주식회사 | 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체 |
| KR101591823B1 (ko) | 2013-12-27 | 2016-02-04 | 재단법인 목암생명공학연구소 | 증가된 유전자 발현능을 갖는 발현벡터 |
| KR101776879B1 (ko) * | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| KR101782632B1 (ko) | 2016-01-11 | 2017-09-27 | 주식회사 녹십자 | 표피 성장 인자 수용체에 특이적으로 결합하는 항체를 유효성분으로 포함하는 암 치료용 조성물 |
| LT3449939T (lt) * | 2016-04-27 | 2022-05-25 | Green Cross Corporation | Farmacinė kompozicija, skirta vėžio metastazės slopinimui, apimanti, kaip veiklųjį ingredientą, antikūną, kuris specifiškai rišasi prie epidermio augimo faktoriaus receptoriaus |
| KR101966362B1 (ko) * | 2017-10-20 | 2019-04-05 | 주식회사 녹십자 | 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| JP7049389B2 (ja) * | 2020-05-01 | 2022-04-06 | グリーン・クロス・コーポレイション | 上皮成長因子受容体に特異的に結合する抗体を有効成分として含む、癌の転移を抑制するための医薬組成物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL181342B1 (pl) * | 1994-03-17 | 2001-07-31 | Merck Patent Gmbh | Jednolancuchowe anty-EGFR Fv i przeciwciala anty-EGFR, czasteczka DNA, sposoby wytwarzania jednolancuchowego przeciwciala anty-EGFR i przeciwciala anty-EGFR oraz kompozycja farmaceutyczna PL PL PL PL PL PL PL |
| EP1500329B1 (en) * | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US20020173629A1 (en) * | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| EP1343820A4 (en) | 2000-10-13 | 2005-09-14 | Uab Research Foundation | ANTI-EPIDERMIC GROWTH FACTOR RECEPTOR SINGLE CHAIN ANTIBODY |
| KR20090125840A (ko) | 2001-06-13 | 2009-12-07 | 젠맵 에이/에스 | 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간 모노클로날 항체 |
| DK1735348T3 (da) * | 2004-03-19 | 2012-07-16 | Imclone Llc | Humant anti-epidermalt vækstfaktorreceptorantistof |
| KR100523732B1 (ko) | 2004-08-27 | 2005-10-26 | 주식회사 녹십자홀딩스 | Ｂ형 간염 바이러스의 표면 항원에 대한 인간항체의가변영역을 삽입할 수 있는 항체발현 플라스미드 |
| KR100635370B1 (ko) | 2005-03-04 | 2006-10-17 | 주식회사 녹십자홀딩스 | ＳｃＦｖ 형태의 항체 라이브러리를 제작하기 위한 항체 ＳｃＦｖ 발현벡터 |
| KR100680141B1 (ko) | 2005-04-20 | 2007-02-07 | 주식회사 녹십자 | 항-ｅｇｆ 수용체 단일클론항체 및 이를 생산하는하이브리도마 세포주 |
| KR100624011B1 (ko) | 2005-04-20 | 2006-09-19 | 주식회사 녹십자 | 항-파상풍 단일클론항체 및 이를 생산하는 하이브리도마세포주 |
| AU2007215013A1 (en) * | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Functional antibodies |
| EP1829895A1 (en) * | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| AU2008227123B2 (en) * | 2007-03-15 | 2014-03-27 | Ludwig Institute For Cancer Research Ltd. | Treatment method using EGFR antibodies and src inhibitors and related formulations |
| WO2009030239A1 (en) | 2007-09-06 | 2009-03-12 | Genmab A/S | Novel methods and antibodies for treating cancer |
-
2009
- 2009-09-29 KR KR1020090092401A patent/KR101108642B1/ko active IP Right Grant
- 2009-11-02 LT LTEP09850100.0T patent/LT2483309T/lt unknown
- 2009-11-02 JP JP2012531990A patent/JP5729839B2/ja active Active
- 2009-11-02 WO PCT/KR2009/006380 patent/WO2011040668A1/en active Application Filing
- 2009-11-02 MY MYPI2012001362A patent/MY163502A/en unknown
- 2009-11-02 US US13/499,155 patent/US8748175B2/en active Active
- 2009-11-02 SI SI200931512A patent/SI2483309T1/sl unknown
- 2009-11-02 DK DK09850100.0T patent/DK2483309T3/en active
- 2009-11-02 CA CA2774427A patent/CA2774427C/en active Active
- 2009-11-02 PT PT98501000T patent/PT2483309T/pt unknown
- 2009-11-02 EP EP09850100.0A patent/EP2483309B1/en active Active
- 2009-11-02 CN CN200980161665.8A patent/CN102574919B/zh active Active
- 2009-11-02 PL PL09850100T patent/PL2483309T3/pl unknown
- 2009-11-02 RU RU2012117753/10A patent/RU2518239C2/ru active
- 2009-11-02 BR BR112012007082-7A patent/BR112012007082B1/pt active IP Right Grant
- 2009-11-02 HU HUE09850100A patent/HUE030733T2/en unknown
- 2009-11-02 ES ES09850100.0T patent/ES2592883T3/es active Active
- 2009-11-02 MX MX2012003662A patent/MX2012003662A/es active IP Right Grant
-
2016
- 2016-11-03 HR HRP20161459TT patent/HRP20161459T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2592883T3 (es) | 2016-12-02 |
| EP2483309A4 (en) | 2013-07-17 |
| BR112012007082B1 (pt) | 2022-07-12 |
| RU2012117753A (ru) | 2013-11-10 |
| JP2013505736A (ja) | 2013-02-21 |
| KR20110034914A (ko) | 2011-04-06 |
| PL2483309T3 (pl) | 2017-02-28 |
| EP2483309A1 (en) | 2012-08-08 |
| PT2483309T (pt) | 2016-09-02 |
| KR101108642B1 (ko) | 2012-02-09 |
| CA2774427A1 (en) | 2011-04-07 |
| LT2483309T (lt) | 2016-11-25 |
| DK2483309T3 (en) | 2016-11-28 |
| BR112012007082A2 (pt) | 2017-06-27 |
| WO2011040668A1 (en) | 2011-04-07 |
| JP5729839B2 (ja) | 2015-06-03 |
| CN102574919A (zh) | 2012-07-11 |
| US20120231021A1 (en) | 2012-09-13 |
| SI2483309T1 (sl) | 2016-10-28 |
| MX2012003662A (es) | 2012-05-08 |
| RU2518239C2 (ru) | 2014-06-10 |
| CN102574919B (zh) | 2014-12-10 |
| EP2483309B1 (en) | 2016-08-17 |
| HUE030733T2 (en) | 2017-05-29 |
| MY163502A (en) | 2017-09-15 |
| US8748175B2 (en) | 2014-06-10 |
| CA2774427C (en) | 2015-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161459T1 (hr) | Protutijela koja se specifično vežu na receptor epidermnog čimbenika rasta | |
| HRP20201634T1 (hr) | Monoklonsko protutijelo protiv interleukina-31 | |
| HRP20191470T1 (hr) | Heterodimerni proteini | |
| RU2019127861A (ru) | ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn | |
| HRP20200034T1 (hr) | Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka | |
| HRP20190897T1 (hr) | Laki lanac humaniziranih miševa | |
| HRP20170254T1 (hr) | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 | |
| HRP20192218T1 (hr) | Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene | |
| HRP20190706T1 (hr) | Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina | |
| UA106607C2 (uk) | Білки специфічного зв'язування і їх застосування | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| HRP20151213T1 (hr) | Anti-c5a protutijela i postupci za uporabu protutijela | |
| HRP20211820T1 (hr) | Anti-tim-3 protutijela i pripravci | |
| JP2019500862A5 (hr) | ||
| RU2014149553A (ru) | Биспецифические анти-vegf/анти-ang-2 антитела | |
| UY30002A1 (es) | Proteínas de unión específicas de factores de crecimiento tipo insulina y usos de las mismas | |
| RU2012153241A (ru) | Антитела к fgfr2 | |
| HRP20130877T1 (hr) | Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena | |
| EA201591131A1 (ru) | Днк-конструкции антитела и способ их применения | |
| AR047372A1 (es) | Anticuerpos contra madcam | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| JP2013523166A5 (hr) | ||
| WO2011127412A3 (en) | Soluble human st-2 antibodies and assays | |
| MY162752A (en) | Alpha-4-beta-7 heterodimer specific antagonist antibody | |
| JP2014518615A5 (hr) |